AccuMetab™ Human CYP2D6∗ 39 Enzyme, Catalytically Active

CAT#: ITS-0426-YL23
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2D6∗ 39 variant for precise pharmacogenetic Phase I profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
The CYP2D6∗ 39 variant represents a specific sequence mutation that can subtly alter the interaction between the enzyme and complex xenobiotic substrates. It is utilized by DMPK researchers seeking comprehensive characterization of CYP2D6 allele-specific metabolism and binding affinities.
Key Features
Rare, allele-specific clearance model; High-reductase configuration for minor metabolite detection; Supports exhaustive precision medicine profiling; Proprietary E. coli expression
Applications
Drug Metabolism Studies, Phenotype Comparison, Polymorphism Impact
Research Areas
ADME; Pharmacogenetics; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry